Quarter
Charts

LENZ THERAPEUTICS, INC.

LENZ

CIK 0001815776 · Quarterly mode · latest period FY2025 (Q3) (ending 2025-09-30) · sourced from SEC EDGAR

At a glance · FY2025 (Q3)

Revenue
$13M
Gross Profit
$13M

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
17/100
  • Profitability
    0ROIC -29.5% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 14.23 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.07x (1.0+ = capital-efficient)
  • Growth
    0Insufficient data
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$827K
investment in PP&E
Stock-based comp (TTM)
$13M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$306M
everything owned
Total liabilities
$22M
everything owed
Stockholders' equity
$284M
shareholder claim

Recent performance · 23 quarters

Revenue
$13M
Net Income↓-63.5% -$6M
$-17M
Free Cash Flow↑+74.5% +$111K
$-38K
Operating Margin
-151.1%

Drill down

LENZ Sankey

See LENZ THERAPEUTICS, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

LENZ Charts

23 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

LENZ Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics